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1. INTRODUCTION 
1.1 Obesity 
Obesity is a term applied to excess body weight with an abnormally high 
proportion of body fat. Thermodynamically speaking, imbalance between energy 
intake (feeding) and energy expenditure (physical activity) leads to obesity (Pilch & 
Bergenhem, 2006). Obesity has emerged as one of the major health concerns in the 
21st century. The morbidity and mortality associated with obesity continue to 
increase and is one of the leading causes of preventable death (Barness, Opitz & 
Gilbert- Barness, 2007). Development of obesity is, however, more complicated 
than that; sedentary life style, genetic factors, medical illness, microbiological 
aspects, social factors and neurobiological mechanisms are also involved 
(Sugerman, 2005; Bleich & Cutler, 2008).  
 Obesity has reached epidemic proportions globally, with more than 1 billion 
adults overweight - at least 300 million of them clinically obese - and is a major 
contributor to the global burden of chronic disease and disability. Often coexisting in 
developing countries with under-nutrition, obesity is a complex condition, with 
serious social and psychological dimensions, affecting virtually all ages and 
socioeconomic groups (Global Strategy on Diet, Physical Activity And Health, 
WHO 2003). Increased consumption of more energy-dense, nutrient-poor foods with 
high levels of sugar and saturated fats, combined with reduced physical activity, 
have led to obesity rates that have risen three-fold or more since 1980 in some areas 
of North America, the United Kingdom, Eastern Europe, the Middle East, the 
Pacific Islands, Australia and China. The obesity epidemic is not restricted to 
industrialized societies; this increase is often faster in developing countries than in 
the developed world (Global Strategy on Diet, Physical Activity And Health, WHO 
2003). A growing public health concern is that the prevalence of obesity among 
children aged 6–19 is up to 16.5% in the USA (Hedley et. al, 2004) and has also 
increased in Europe, Asia, Africa and South American countries (Antipatis  & Gill, 
2001 ). Despite increased attention given to overweight and obesity by every major 
body concerned with public health, including the National Institutes of Health (NIH) 
(National Task Force, 1994) the Centers for Disease Control (Mokdad et. al., 2001), 
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the United States Department of Agriculture (Freedman King & Kennedy, 2001) and 
the World Health Organization (WHO, 2000) primary and secondary prevention 
efforts have generally been disappointing.  
 Obesity impacts many facets of society. For example, it is economically 
costly to society (World Health Organization, 1998) increases mortality rate 
(Allison, Fontaine, Manson, Stevens & VanItallie, 1999) reduces quality of life 
(Fontaine, Bartlett & Barofsky, 2000) and increases the risk of various morbidities 
(Billington, 2000). Extreme obesity has been estimated to truncate the lifespan of 
young adults by 5–20 years (Fontaine, Bartlett & Barofsky, 2000). The medical 
problems caused by obesity begin at the head and end at the toes and involve almost 
every organ in between. Several of these problems contribute to the earlier mortality 
associated with obesity and include coronary artery disease, severe hypertension that 
may be refractory to medical management, impaired cardiac function, adult-onset 
(type 2) diabetes mellitus, obesity hypoventilation and sleep apnea syndromes, 
cirrhosis, venous stasis and hypercoagulability with an increased risk of pulmonary 
embolism, and necrotizing panniculitis (Sugerman, 2005 ).   
 The association of obesity with T2DM (Type 2 DM) has been observed in 
comparisons of different populations and within populations (West & Kalbfleisch, 
1971; Joslin, 1921). Approximately 10% of the obese population develop T2DM 
(Harris, Flegal & Cowie, 1998). This may be because of “glucotoxicity” (expression 
of glucose allostasis and increase in „allostatic load), “lipotoxicity” fatty acid supply 
to peripheral tissues impairs glucose uptake and storage in the muscle (Boden, 1997; 
Balasse & Neef, 1973; Gomez, Jequier, Chabot, Buber, & Felber, 1972; Kumar, 
Boulton, Beck-Nielsen, 1996) and adipokines (adipose tissue) hormones that are 
secreted by the adipose tissue (TNF-a, IL-6, complement C3, MIF, adiponectin) are 
associated with insulin resistance, often independently of the degree of adiposity 
(Straczkowski, et. al., 2002; Weyer, 2000; Weyer, Funahashi  & Tanaka, 2001; 
Vozarova, Metz & Stefan, 2002). Unfortunately, with the exception of surgery (a 
procedure appropriate for only a minority of obese individuals), available treatments 
for obesity are, at best, of modest efficacy. With regard to nonsurgical treatments for 
obesity (Ayyad & Andersen, 1999), in a quantitative synthesis of the literature, 
found that even in the best of conditions, the median percentage of patients who 
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achieved and maintained clinically meaningful weight loss for at least 3– 5 years 
was only about 20%, whereas others have reported that of those who lose weight, 
90–95% eventually regain it (World Health Organization, 2000). 
 Pre-clinical evaluatory study of compound can be done by using three animal 
models i.e. drug induced obesity; food induced obesity and genetically modified 
C57BL/6J female mice. Theneuro active steroid, progesterone is a female 
reproductive hormone. Its level increases during the later phase of the menstrual 
cycle and controls the secretary phase of the endometrium. Substantial evidence 
links progesterone excess in pathophysiology of eating and affective disorders. 
Some reports suggest the use of progesterone containing preparations as 
contraceptive or for the hormone replacement therapy to cause sufficient weight gain 
by causing hyperphagia and increased fat deposition in the body (Amatayakul, 
Sivasomboon & Thanangkul, 1980; Wallace, Shively & Clarkson, 1999). Reports 
also suggest that progesterone can produce these effects by inducing myriad of 
neurotransmitter changes of which alterations of serotonin level can be important. 
With this setting we have chosen this neuroactive to induce obesity in female mice.  
It is well known that high fat intake and sedentary life style, white collar jobs, lack 
of exercise etc.  causes fat accumulation an increase in body weight. Cafeteria diets 
animal models of obesity have been reported to bear close resemblance to human 
obesity (Sclafani & Springer, 1976). Cafeteria diet is the combination of different 
composition like supermarket highly palatable food. Cafeteria diets have been 
previously reported to increase energy intake and cause obesity in humans as well as 
animals (Bull 1988; Rothwell, Stock & Warwick, 1983).  In general, C57BL/6J 
(ob/ob) models have been used for investigation of human obesity and metabolic 
syndrome (Feldstein, et. al., 2003). When raised on a low-fat diet, the C57BL/6J 
(ob/ob) mice are lean and euglycemic with normal insulin levels and blood pressure. 
However, when raised on a high-fat (HF) diet, animals develop central adiposity, 
hyperinsulinemia, hyperglycemia and hypertension (Surwit, Kuhn, Cochrane, 
McCubbin & Feinglos, 1988). These syndromes appear to be related to 
abnormalities in adrenergic control of adipocyte function, which, in turn, appear to 
be related to hyperinsulinemia (Surwit, Kuhn, Cochrane, McCubbin, & Feinglos, 
1988). Also, the development of insulin resistance, hyperglycemia and obesity in the 
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C57BL/6J (ob/ob) mice closely parallel the progression of common forms of the 
human diseases (Crevel, Friend, Goodwin & Parish, 1992).  
 Ayurvedic system of medicine is one of the oldest system of medicine 
having a history of more than 3000 years. Several prototype derived from these 
herbal medicines are in use for various kind of disease and disorders. It not only 
gives new molecule but also with newer mechanism of action, hence is called Gold 
mine. Several infusions or decoctions of plants used in traditional medicine to 
reduce obesity could be utilized to delete the clinical side effects of the current 
chemically formulated antiobesity agents; examples include Camellia sinensis (L.) 
Kuntze (Theaceae), Chlorella pyrenoidosa Chick. (Oocystaceae), Citrus aurantium 
L. (Rutaceae), Garcinia cambogia L. (Clusiaceae), Lagerstroemia speciosa (L.) 
Pers. (Lythraceaea), Panax ginseng C.A. Meyer (Araliaceae), Salix matsudana 
Koidzumi (Salicaceae), Nelumbo nucifera Gaertn. (Nymphaeaceae) and Ste llaria 
media  and Clerodendrum phlomites (Calapai, et, al., 1999; Han et. al., 2003; 
Hidaka, Okamoto & Arita, 2004; Dilip, Manashi & Nazim, 2005; Katewa & Galav, 
2006). A large study of literature indicates that substantial progress has been made 
concerning our knowledge of bioactive components in plant foods and their links to 
obesity. For the present research protocol we have chosen Clerodendrum serratum 
linn. to evaluate its anti-obesity.As per the literature survey it was found that 
flavonides, sitosterols, tannins and saponines have shown the anti-obesity activity by 
various mechanisms, this  plant have shown the presence of some common 
phytoconstituents in their extracts like sitosterols, triterpenoids, flavonoids and 
tanins etc. Moreover traditional system of Indian medicine also claims for its anti-
obesity activity. With this back ground we have selected this plant for its 
phytochemical analysis, screening its anti-obesity to substantiate the folklore claim.   
1.2. Disease profile:  
1.2.1. Definition:   
 Obesity is a chronic disease that causes risks ill health, impaired quality of 
life, and premature mortality. Obesity results from a complex interaction of genetic 
predisposition, environmental, societal and individual psychological factors that all 
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summate to produce a chronic positive energy balance (Finer, 2002).Obesity results 
from a positive energy balance i.e., when caloric intake chronically exceeds energy 
expenditure. This in turn causes excess of adipose tissue mass with body mass index 
(BMI) > 30 kg/m2 ) (Caterson, 1999). 
 The classification of body weight according to WHO is as follows:  
BMI < 18.5 Underweight 
BMI 18.5 – 24.9 Normal 
BMI 25 - 29.9  Over weight 
BMI 30 – 39.9 Obese 
BMI 40 or higher Severely obese 
 
 Although there is a correlation between obesity and cardiac disease, BMI is 
not a precise predictor of cardiovascular disease; absolute waist circumference or 
waist to hip ratio are more precise measures of central obesity and correlate better to 
health risks than BMI (Janssen, Katzmarzyk & Ross, 2004).   
 According to the American Cancer Society, obesity cost an estimated $75 
billion in 2003 because of the long and expensive treatment for several of its 
complications. According to the National Institute of Health, $75 -$125 billion is 
spent on indirect and direct costs due to obesity-related 
diseases.(http://www.phitamerica.org/Cost_of_Obesity_Counter.htm) 
 Eric Schlosser in his book "Fast Food Nation" states that the annual health 
care costs in the United States stemming from obesity approaches $240 billion.   
1.2.2. Obesity and insulin resistance diabetes   
 Obesity-associated insulin resistance is a major risk factor for type 2 diabetes 
and cardiovascular disease. In the past decade, a large number of endocrine, 
inflammatory, neural, and cell-intrinsic pathways have been shown to be 
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dysregulated in obesity. Although it is possible that one of these factors plays a 
dominant role, many of these factors are interdependent, and it is likely that their 
dynamic interplay underlies the pathophysiology of insulin resistance. 
Understanding the biology of these systems will inform the search for interventions 
that specifically prevent or treat insulin resistance and its associated pathologies. 
(Mohammed Qatanani & Mitchell A. Lazar, 2007). 
 One of the most common physical consequences of obesity is the 
development of insulin resistance. Insulin resistance is an irreversible and 
progressive condition; once the body's cells do not respond to insulin, the glucose 
levels must be controlled through human intervention and monitoring. In obese 
persons, insulin resistance is another stressor on the body that heightens the 
considerable risk of early mortality. Insulin resistance has other serious 
consequences, as it will often lead to the progressive illness known as the metabolic 
syndrome, which is the combination of a series of distinct physical conditions. Each 
component of the metabolic syndrome is potentially dangerous to human health 
when present alone: type 2 diabetes mellitus, hypertension, hyperlipidimedia (the 
production of excessive levels of low density lipoproteins, a harmful cholesterol that 
causes plaque to form inside the blood vessels, which causes a narrowing and the 
potential for restricted blood flow), cardiovascular disease, renal failure, risk of 
various infections, particularly when the skin is cut or a sore develops.  
1.3. Epidemiology 
 Globally, more than 1.1 billion adults worldwide are overweight, and 312 
million of them are obese. In addition, at least 155 million children worldwide are 
overweight or obese, according to the International Obesity Task Force (Childhood 
Report). This task force and the World Health Organization (WHO) have revised the 
definition of obesity to adjust for ethnic differences, and this broader definition may 
reflect an even higher prevalence with 1.7 billion people classified as overweight 
worldwide (N Engl 2007). 
 About 18 million people die every year from cardiovascular disease, for 
which diabetes and hypertension are major predisposing factors. Propelling the 
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upsurge in cases of diabetes and hypertension is the growing prevalence of 
overweight and obesity (Report of the International Bioethics Committee of 
UNESCO (IBC) on Social Responsibility and Health). 
 Data from the National Health and Nutrition Examination Surveys 
(NHANES) show that the percent of the American adult population with obesity 
(BMI > 30) has increased from 14.5% (between 1976 and 1980) to 30.5% (between 
1999 and 2000). As many as 64% of U.S. adults = 20 years of age were overweight 
(defined as BMI > 25) between the years of 1999 and 2000. Extreme obesity (BMI = 
40) has also increased and affects 4.7% of the population. The increasing prevalence 
of medically significant obesity raises great concern. Obesity is more common 
among women and in the poor; the prevalence in children is also rising at a 
worrisome rate (Kasper, et. al., 2005). 
 In the past 20 years, the rates of obesity have tripled in developing countries 
that have been adopting a Western lifestyle involving decreased physical activity 
and overconsumption of cheap, energy-dense food. Such lifestyle changes are also 
affecting children in these countries; the prevalence of overweight among them 
ranges from 10 to 25% and the prevalence of obesity ranges from 2 to 10%. The 
Middle East, Pacific Islands, Southeast Asia and China face the greatest threat.  In 
India currently, almost 1 in 5 men and over 1 in 6 women are overweight. In some 
urban areas, the rates are as high as 40%. Published in the Lancet the Organization 
for Economic Co- operation and Development (OECD), the study warns that low-
income countries cannot cope with the health consequences of wide scale obesity 
(Kounteya, 2010).  
 The growing prevalence of type 2 diabetes, cardiovascular disease,and some 
cancers is tied to excess weight. The burden of these diseases is particularly high in 
the middle-income countries of Eastern Europe, Latin America, and Asia, where 
obesity is the fifth-most-common cause of the disease burden ranking just below 
underweight. The high risk of both diabetes and cardiovascular  disease associated 
with obesity in Asians may be due to a predisposition  to abdominal obesity, which 
can lead to the metabolic syndrome and impaired glucose tolerance. The serious 
cardiovascular complications of obesity and diabetes could overwhelm developing 
8 
 
 
countries that are already straining under the burden of communicable diseases. The 
increase in the prevalence of type 2 diabetes is closely linked to the upsurge in 
obesity. About 90% of type 2 diabetes is attributable to excess weight. Furthermore, 
approximately 197 million people worldwide have impaired glucose tolerance, most 
commonly because of obesity and the associated metabolic syndrome. This number 
is expected to increase to 420 million by 2025.  
 Cardiovascular disease is considerably greater among obese people, and this 
group has an incidence of hypertension that is five times the incidence among people 
of normal weight. Hence, overweight and obesity are contributing to a global 
increase in hypertension.  1 billion people had hypertension in 2000 and 1.56 billion 
people are expected to have this condition by 2025 (Kearney, Whelton, Reynolds, 
Muntner & Whelton, 2005).  
 Obesity, diabetes, and hypertension also affect the kidneys. Diabetic 
nephropathy develops in about one third of patients with diabetes and its incidence is 
sharply increasing in the developing world, with the Asia–Pacific region being the 
most severely affected. According to a survey published in 2003, diabetic 
nephropathy was the most common cause of end-stage renal disease in 9 of 10 Asian 
countries, with an incidence that had increased from 1.2% of the overall population 
with end-stage renal disease in 1998 to 14.1% in 2000 (Parvez hossain,et.al.,  2007).   
1.4. Etiology of obesity   
 The exact etiology of obesity is unclear. The multiple causative factors like 
genetic, environmental, nutritional, physiological, psychological, social and cultural 
factors have been linked to its development and progression (Rippe, Crossley& 
Ringer, 1998).  
 Though the molecular pathways regulating energy balance are beginning to 
be illuminated, the causes of obesity remain elusive. In part, this reflects the fact that 
obesity is a heterogeneous group of disorders. At one level, the pathophysiology of 
obesity seems simple: a chronic excess of nutrient intake relative to the level of 
energy expenditure. However, due to the complexity of the neuroendocrine and 
metabolic systems that regulate energy intake, storage, and expenditure, it has been 
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difficult to quantitate all the relevant parameters (e.g., food intake and energy 
expenditure).  
1.4.1. Environmental factors  
 The current environmental risk factors include over consumption of energy 
(increase in fat to carbohydrate ratio) and decrease in physical activity. These factors 
offer more reasonable explanation for the recent dramatic surge in the prevalence of 
obesity (Poppitt, 1995).   
1.4.2. Nutritional factors  
 Numerous metabolic studies have shown that high fat diets may lead to a 
high energy intake and hyperphagia. The reason may be that fat has a weaker effect 
on the satiety centre and on heat production (diet-induced thermogenesis) and it 
possesses a higher energy density compared to carbohydrates. Also fats are highly 
palatable and heighten the flavour of food stuffs which leads to their passive 
overconsumption. This ultimately increases fat deposits and causes obesity and 
related problems (Zhang, et. al., 1994).  
1.4.3. Physiological factors   
 These involve the impairment of the central mechanism regulating appetite 
and food intake which is thought to be regulated by a complex interplay of 
neurotransmitters in the hypothalamic region of the brain. Approximately 1 - 2% of 
obesity can be ascribed to lesions in hypothalamic regulatory centres. Such lesions 
may be due to trauma, tumours, inflammatory processes, or carotid artery aneurysms 
(Bray & York, 1979).   
1.4.4. Psychological factors  
 The psychogenic theory of obesity long held that obesity resulted from an 
emotional disorder in which food intake, relieved the anxiety and depression to 
which obese persons are usually susceptible. Stress associated with traumatic 
emotional events has been held responsible for certain cases of obesity and has been 
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implicated in the pathogenesis of eating disorders such as night-eating syndrome and 
bulimia (Kissebah et. al., 1982).  
1.5. Role of Genes versus Environment    
 Obesity is commonly seen in families, and the hereditability of body weight 
is similar to that for height. Inheritance is usually not Mendelian, however, and it is 
difficult to distinguish the role of genes and environmental factors. Adoptees usually 
resemble their biologic rather than adoptive parents with respect to obesity, 
providing strong support for genetic influences. Likewise, identical twins have very 
similar BMIs (Body Mass Index) whether reared together or apart, and their BMIs 
are much more strongly correlated than those of dizygotic twins. These genetic 
effects appear to relate to both energy intake and expenditure. 
 Whatever the role of genes, it is clear that the environment plays a key role 
in obesity, as evidenced by the fact that famine prevents obesity in even the most 
obesity-prone individual. In addition, the recent increase in the prevalence of obesity 
in the United States is too rapid to be due to changes in the gene pool. Undoubtedly, 
genes influence the susceptibility to obesity when confronted with specific diets and 
availability of nutrition. Cultural factors are also important these relate to both 
viabilityand composition of the diet and to changes in the level of physical activity. 
In industrial societies, obesity is more common among poor women, whereas in 
underdeveloped countries, wealthier women are more often obese. In children, 
obesity correlates to some degree with time spent watching television. High fat diets 
may promote obesity, as may diets rich in simple (as opposed to complex) 
carbohydrates (Kasper et. al., 2005).  
1.6. Specific Genetic Syndromes   
 For many years obesity in rodents has been known to be caused by a number 
of distinct mutations distributed through the genome. Most of these single-gene 
mutations cause both hyperphagia and diminished energy expenditure, suggesting a 
link between these two parameters of energy homeostasis. Identification of the ob 
gene mutation in genetically obese (ob/ob) mice represented a major breakthrough in 
the field. The ob/ob mouse develops severe obesity, insulin resistance, and 
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hyperphagia, as well as efficient metabolism (e.g., it gets fat even when given the 
same number of calories as lean littermates). The product of the ob gene is the 
peptide leptin, a name derived from the Greek root leptos, meaning thin. Leptin is 
secreted by adipose cells and acts primarily through the hypothalamus. Its level of 
production provides an index of adipose energy stores (Fig 1). High leptin levels 
decrease food intake and increase energy expenditure. Another mouse mutant, 
db/db, which is resistant to leptin, has a mutation in the leptin receptor and develops 
a similar syndrome. The OB gene is present in humans and expressed in fat. Several 
families with morbid, early-onset obesity caused by inactivating mutations in either 
leptin or the leptin receptor have been described, thus demonstrating the biologic 
relevance of leptin in humans. The obesity in these individuals begins shortly after 
birth, is severe, and is accompanied by neuroendocrine abnormalities. The most 
prominent of these is hypogonadotropic hypogonadism, which is reversed by leptin 
replacement. Central hypothyroidism and growth retardation are seen in the mouse 
model, but their occurrence in leptin-deficient humans is less clear. To date, there is 
no evidence to suggest that mutations or polymorphisms in the leptin or leptin 
receptor genes play a prominent role in common forms of obesity. Mutations in 
several other genes cause severe obesity in humans; each of these syndromes is rare. 
Mutations in the gene encoding proopiomelanocortin (POMC) cause severe obesity 
through failure to synthesize a-MSH, a key neuropeptide that inhibits appetite in the 
hypothalamus. The absence of POMC also causes secondary adrenal insufficiency 
due to absence of adrenocorticotropic hormone (ACTH), as well as pale skin and red 
hair due to absence of MSH. Proenzyme convertase 1 (PC-1) mutations are thought 
to cause obesity by preventing synthesis of a-MSH from its precursor peptide, 
POMC. a- MSH binds to the type 4 melanocortin receptor (MC4R), a key 
hypothalamic receptor that inhibits eating. Heterozygous mutations of this receptor 
appear to account for as much as 5% of severe obesity. These five genetic defects 
define a pathway through which leptin (by stimulating POMC and increasing MSH) 
restricts food intake and limits weight.  
  In addition to these human obesity genes, studies in rodents reveal several 
other molecular candidates for hypothalamic mediators of human obesity or 
leanness. The tub gene encodes a hypothalamic peptide of unknown function; 
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mutation of this gene causes late-onset obesity. The fat gene encodes 
carboxypeptidase E, a peptide- processing enzyme; mutation of this gene is thought 
to cause obesity by disrupting production of one or more neuropeptides. AgRP is 
coexpressed with NPY in arcuate nucleus neurons. AgRP antagonizes a- MSH 
action at MC4 receptors, and its overexpression induces obesity. In contrast, a 
mouse deficient in the peptide MCH, whose administration causes feeding, is lean. 
A number of complex human syndromes with defined inheritance are associated 
with obesity. Although specific genes are undefined at present, their identification 
will likely enhance our understanding of more common forms of human obesity. In 
the Prader- Willi syndrome, obesity coexists with short stature, mental retardation, 
hypogonadotropic hypogonadism, hypotonia, small hands and feet, fish-shaped 
mouth, and hyperphagia. Most patients have a chromosome 15 deletion. Laurence-
Moon-Biedl syndrome is characterized by obesity, mental retardation, retinitis 
pigmentosa, polydactyly, and hypogonadotropic hypogonadism (Kasper, et. al., 
2005).  
1.7. Other Specific Syndromes Associated with Obesity:  
 InsulinomaPatients with insulinoma often gain weight as a result of 
overeating to avoid hypoglycemia symptoms. The increased substrate plus high 
insulin levels promote energy storage in fat. This can be marked in some individuals 
but is modest in most (Kasper, et. al., 2005).  
1.7.1. Cushing’s syndrome   
 Although obese patients commonly have central obesity, hypertension, and 
glucose intolerance, they lack other specific stigmata of Cushing‘s syndrome. 
Nonetheless, a potential diagnosis of Cushing‘s syndrome is often entertained. 
Cortisol production and urinary metabolites (17OH steroids) may be increased in 
simple obesity. Unlike in Cushing‘s syndrome, however, cortisol levels in blood and 
urine in the basal state and in response to corticotropin-releasing hormone (CRH) or 
ACTH are normal; the overnight 1-mg dexamethasone suppressiontest is normal in 
90%, with the remainder being normal on a standard 2-day low-dose dexamethasone 
suppression test. Obesity may be associated with local reactivation of cortisol in fat 
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by 11 ß hydroxysteroid dehydrogenase 1, an enzyme that converts cortisone to 
cortisol (Kasper et. al., 2005).  
1.7.2. Hypothyroidism 
 The possibility of hypothyroidism should be considered, but it is an 
uncommon cause of obesity; hypothyroidism is easily ruled out by measuring 
thyroid-stimulating hormone (TSH). Much of the weight gain that occurs in 
hypothyroidism is due to myxedema (Kasper et. al., 2005).  
1.7.3. Craniopharyngioma and other disorders involving the  
hypothalamus   
 Whether through tumors, trauma, or inflammation, hypothalamic dysfunction 
of systems controlling satiety, hunger, and energy expenditure can cause varying 
degrees of obesity. It is uncommon to identify a discrete anatomic basis for these 
disorders. Subtle hypothalamic dysfunction is probably a more common cause of 
obesity than can be documented using currently available imaging techniques. 
Growth hormone (GH), which exerts lipolytic activity, is diminished in obesity and 
is increased with weight loss. Despite low GH levels, insulin-like growth factor 
(IGF) I (somatomedin) production is normal, suggesting that GH suppression is a 
compensatory response to increased nutritional supply (Kasper et. al., 2005). 
1.8. TYPES OF OBESITY 
1.8.1. Central (android) (apple) versus Peripheral (gynoid) (pear)  
 It has been noted that central (android, more prevalent in men) obesity is 
associated with a higher mortality than peripheral (gynoid, more prevalent in 
women) obesity. This discrepancy has been attributed to the fact that visceral 
adipose tissue is metabolically more active than subcutaneous fat, causing a greater 
rate of glucose production, type II diabetes mellitus, and hyperinsulinism. Increased 
insulin secretion is thought to increase sodium reabsorption and result in 
hypertension. Central obesity is also associated with increased production of 
cholesterol, primarily in the form of low-density lipoprotein, leading to increased 
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incidence of atherosclerotic cardiovascular disease and gallstones. The increased 
visceral fat has been related to an increased waist: hip ratio or, in more common 
terms, as the ―apple versus ―pear  distribution of fat (Figure 1). Computed 
tomography (CT) scans, however, have noted a much better correlation between 
anterior-posterior abdominal diameter and visceral fat distribution than the waist: 
hip ratio, especially in women with both central and peripheral obesity. In this 
situation the peripheral obesity ―dilutes the central obesity as measured by the 
waist: hip ratio, so either waist circumference alone or sagittal abdominal diameter 
should be used as a measurement of central obesity.  
 A recent study documented increased bladder pressure in morbidly obese 
women that was associated with a high incidence of urinary incontinence. It is quite 
probable that much of the comorbidity of severe obesity is related to increased intra- 
abdominal pressure secondary to a central fat distribution and that urinary bladder 
pressure, surrogate for intra-abdominal pressure, is highly correlated with sagittal 
abdominal diameter or waist circumference (Sugerman, 2005). With analysis of 
surface area and volume, analysis of subcutaneous fat and intra-abdominal visceral 
fat could be done and a novel classification of obesity was proposed - visceral fat 
obesity (VFO) and subcutaneous fat obesity (SFO) based on the ratio of visceral fat 
area and subcutaneous fat area (V/S ratio) at the level of umbilicus (Yamashita, et. 
al. 1996; Arner, 1998). 
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Figure 1: Left figure indicating the apple shape obesity where the fat mainly 
deposited above the waist where as right figure indicating pear shaped obesity where 
fat is mainly deposited below the waist. 
1.8.2. Complications of obesity 
 Direct association between obesity and several diseases cause number of 
problems i.e., difficulties with daily activities to serious health issues.  
 Obesity Comorbidity: “the top of the head to the tip of the toes and almost 
every organ in-between”. (Sugerman, 2005) 
Head:  
Brain Depression Stroke Headaches Hypertension Pseudotumor cerebri: Headaches  
I.  Optic nerve: Visusal field (Blindness) 
II. Oculomotor nerve palsy 
III. Trigeminal nerve: tic doloreaux  
IV. Facial nerve: Bell‘s palsy  
V. Auditory nerve: pulsatile tinnitus  
Eyes: 
Diabetic retinopathy  
Mouth/throat Sleep apnea  
Chest: 
Breast cancer  
Obesity hypoventilation 
Heavy chest wall 
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Elevated diaphragm 
Increased Intrathoracic pressure 
Decreased expiratory reserve volume  
Heart:  
Left ventricular hypertrophy  
Eccentric: Increased cardiac output  
Concentric: increased peripheral vascular resistance 
Increased cardiac filling pressures (CVP, PAP, WP)  
Right heart failure  
Tricuspid insufficiency  
Esophagus:  
Acid reflux 
Asthma 
Adenocarcinoma 
Esophageal varices   
Abdomen:  
Gallbladder Cholecystitis  
Adenocarcinoma  
Liver:  
Non-alcholic liver disease (NALD) 
Non-alcoholic steatohepatitis (NASH)  
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Cirrhosis Type 2 diabetes mellitus  
Spleen:  
Splenomegaly (portal hypertension)  
Hypersplenism (portal hypertension)  
Pancreas:  
Type 2 diabetes mellitus 
Necrotizing pancreatitis  
Colon  
Adenocarcinoma  
Diverticulitis  
General:  
Difficulty diagnosing peritonitis 
Hernia 
Incsional Inguinal Spighelian  
Wound infection 
Lymphatic stasis  
Kidney:  
Hypertension 
Proteinuria  
Renal cell carcinoma  
Urinary bladder Stress incontinence  
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Ovaries/uterus:  
Increased estradiol, 
androstenedione  
Polycystic ovary syndrome,  
Stein–Leventhal syndrome 
Infertility  
Dysmenorrhea 
Hirsutism  
Endometrial carcinoma 
Breast cancer  
Pregnancy complications  
Maternal, fetal mortality  
Pre-eclampsia,  
Eclampsia  
Gestational diabetes 
Thromboembolism  
 Complicated childbirth: cephalopelvic disproportion, increased cesarean 
section fetal complications: macrosomia, shoulder dystocia, small for gestational age  
Prostate: adenocarcinoma  
Anus:  
Periananal abscess  
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Necrotzing panniculitis  
Integument:  
Necrotizing panniculitis  
Hirsutism 
Increased risk of operative complications 
Colectomy 
Hysterectomy 
Kidney, liver transplantation  
Spine:  
Herniated disc  
Upper Extremties:  
Shoulder girdle pain Edema  
Lower extremities:  
Osteoarthritis  
Hip arthralgia 
Knee arthralgia  
Venous stasis:  
Edema  
Thrombophlebitis  
Stasis ulcers 
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Pulmonary embolism 
Lymphedema  
Toes:  
Diabetic neuropathy Diabetic ulcers   
1.9. The adipocyte and adipose tissue   
 Adipose tissue is composed of the lipid-storing adipose cell and a 
stromal/vascular compartment in which preadipocytes reside. Adipose mass 
increases by enlargement of adipose cells through lipid deposition, as well as by an 
increase in the number of adipocytes. The process by which adipose cells are 
derived from a mesenchymal preadipocyte involves an orchestrated series of 
differentiation steps mediated by a cascade of specific transcription factors. One of 
the key transcription factors is peroxisome proliferatoractivated receptor  
(PPAR ), a nuclear receptor that binds the thiazoladinedione class of insulin-
sensitizing drugs used in the treatment of type 2 diabetes. 
 Although the adipocyte has generally been regarded as a storage depot for 
fat, it is also an endocrine cell that releases numerous molecules in a regulated 
fashion. These include the energy balance-regulating hormone leptin, cytokines such 
as tumor necrosis factor (TNF) , complement factors such as factor D (also known 
as adipsin), prothrombotic agents such as plasminogen activator inhibitor I, and a 
component of the blood pressure regulating system, angiotensinogen. Adiponectin 
(or ACRP30) enhances insulin sensitivity andlipid oxidation, whereas resistin may 
induce insulin resistance. These factors, and others not yet identified, play a role in 
the physiology of lipid homeostasis, insulin sensitivity, blood pressure control, and 
coagulation and are likely to contribute to obesity-related pathologies.  
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1.10. Management of obesity 
 Currently three options are available for the treatment of obesity and 
associated complications are non pharmacological treatment, pharmacotheropy and 
surgical procedures, each of these are having their own advantageous and 
drawbacks.    
1.10.1 Non Pharmacological approach 
 Non-pharmacological measures are preferred for many reasons for many 
reasons including adverse effects of anti-obesity drugs, contraindications or allergic 
reactions to drugs, perceptions of adverse effects of drugs, or personal preference for 
natural or alternative therapies. A more aggressive integrative approach to the 
management of obesity is recommended to improve outcomes, minimize adverse 
effects, and reduce health care costs. Non-pharmacological treatment consists of 
lifestyle modification, reduction of total caloric intake and regular aerobic exercise.  
Diet:   
 There is no evidence to suggest that specific components of the diet (ie, 
carbohydrate, fat, protein, vitamins, micronutrients) influence the ways in which 
food energy is absorbed or used. Therefore, the main dietary approach for reducing 
weight is to reduce the total amount of calories consumed, and this is best achieved 
by a reduction in the amount of fat in the diet and calories from soft drinks. A 
moderate decrease in caloric balance (500-1000 kcal/d) will result in a slow but 
progressive weight loss (Franz, et. al., 2002). In addition, evidence suggests that the 
components of diet currently recommended as healthy, including low consumption 
of saturated and trans fats, intake of carbohydrates that are rich in dietary fiber, high 
fruit and vegetable intake, and the inclusion of low-fat dairy foods - are likely to 
protect against metabolic syndrome (Feldeisen & Tucker, 2007). However, even if 
dietary efforts are the primary treatment approach for people who are overweight or 
obese, dietary counseling interventions generally produce only modest weight loss 
that diminishes over time, as emphasized in a recent meta-analysis (Dansinger et. 
al., 2007).   
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Exercise:  
 Most obesity studies have not adequately measured physical activity and 
functional capacity, and the independent contributions of "fitness" versus "fatness" 
to health risks associated with obesity are still being debated (Blairi & Church, 
2004). Nonetheless, the role of physical activity as a treatment and/or preventive 
strategy for combating obesity has been the subject of substantial research. A 
systematic review of the literature concluded that limited evidence from a number of 
studies that used imaging techniques to quantify changes in abdominal obesity 
suggests a beneficial influence of physical activity on reduction of abdominal fat and 
VAT in overweight and obese subjects (Kay & Fiatarone, 2006). Reductions in VAT 
and total abdominal fat may occur in the absence of changes in body mass and waist 
circumference. Because the deposition of fat in the abdomen and in non-adipose 
tissues such as liver (Yki-Jiirvinen, 2005) and muscle (Moro, Bajpeyi & Smith, 
2008) plays a major role in the development of obesity-related health risks, these 
depots have emerged as alternative targets for obesity treatment and may partly 
explain the utility of physical activity with only minimal or no weight loss in the 
treatment of obesity (Janiszewsk & Ross, 2007). However, more rigorous studies are 
needed to confirm these observations.  
Lifestyle Modifications:   
 The primary approach for achieving weight loss, in the vast majority of 
cases, is lifestyle modification, including a reduction in energy intake and an 
increase in physical activity (Scheen, 2008; Scheen, 2004).   
1.10.2. Pharmacological measures of obesity:  
 Obesity therapies include reducing nutrient absorption and applying 
anorectic drugs, thermogenic drugs or drugs that affect lipid mobilization and 
utilization. With the exception of Orlistat, a recently approved gastrointestinal lipase 
inhibitor, all drugs approved for the treatment of obesity are either 
catecholaminergic or serotonergic CNS-active (activating the sympathetic nervous 
system) anorectic agents. Since some of these drugs may lead to dependency, they 
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are recommended for short-term use like amphetamine-like drugs. Upon termination 
of therapy with these drugs, weight is rapidly regained in many cases (Kang, et. al., 
2004). 
 Dinitrophenol was the first synthetic thermogenic drug used to treat obesity, 
unfortunately during clinical use there were number of deaths from multisystem 
side- effects and the drug was rapidly withdrawn. The discovery of ephedrine led to 
synthesis of amphetamines which suppressed appetite and food intake, but 
stimulation actions of these drugs produced strong liability to abuse (Finer, 2002).    
 Currently used anti-obesity drugs include inhibitors of 5-hydroxytryptamine 
uptake like fenfluramine and sympathomimetics like phentermine. Fenfluremine is 
reported to cause pulmonary hypertension and heart valve defects whereas 
phentermine may produce rebound weight gain. ALT-962 is a new molecule as the 
sole competitor of orlistat, which is found to be safe and well tolerated in phase I of 
clinical trials, is now being forwarded for phase II and III studies (Goyal & Shah, 
2002).  
 Concern of risk factors associated with anti-obesity drugs the British 
National Formulary recommends thatdrugs (for obesity) should only be considered 
for those with a BMI of 30 or greater if supervised diet, exercise and behaviour 
modification fail to achieve a realistic reduction in weight(Greenway, 1996).  
 Surgery can provide palliation for severe obesity when all medical 
approaches have failed. It can result in decreased food intake (gastric procedures - 
jaw wiring, vertical banded gastroplasty, gastric stapling), affect calorie absorption 
(intestinal shunting, biliopancreatic bypass), or remove excess fat (lipectomy, 
liposuction) (Pasquali & Casimirri, 1993).  
1.10.3. Surgical Approach:   
 The contrasting effects of various surgical procedures on the metabolic 
profile have underscored the crucial role of intra-abdominal adipose tissue (ie, VAT) 
rather than subcutaneous abdominal adipose tissue (Figure 2). Indeed, whereas large 
volume liposuction that reduces abdominal subcutaneous fat depots by 8 to 10 kg 
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has almost no favorable effects on the metabolic profile, Omental fat reduction 
(corresponding to only 0.8% of total body fat) in connection with adjustable gastric 
banding results in a dramatic improvement in insulin resistance and associated 
glucose disturbances (Klein, et. al., 2004; Thörne, Lönnqvist, Apelman, Hellers, & 
Arner, 2002). Bariatric surgical procedures (i.e. gastroplasty, gastric bypass) are the 
only procedures that provide marked and sustained weight reduction in morbidly 
obese patients, leading to improvements in associated metabolic disorders, 
especially type 2 DM, and a more favorable long-term prognosis, including a 
reduction in total mortality (Sjöström, et. al., 2007). However, considering the 
risk/benefit ratio of bariatric surgery, it may not yet be considered an early option in 
the management of the abdominally obese patient.   
 
Figure 2. Surgical method (Surgical Gastric sleeve Method) 
1.11. Herbal plants against Obesity 
 Medicinal plants and plant extracts represent the oldest and most widespread 
form of medication. At least 25% of the active compounds in currently prescribed 
synthetic drugs were first identified in plant sources (Balandrin, Klocke, Wurtele & 
Bollinger, 1985).       
 Dissatisfaction with the high costs and potentially hazardous side effects of 
pharmaceuticals have resulted in a larger percentage of people in the United States 
purchasing and exploring the applications of medicinal plants than before (Kessler 
et. al., 2001). Several plants like willow, poppy, foxglove, cinchona, aloe and garlic 
have been verified as medicinally beneficial through repeated clinical testing and 
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laboratory analyses (Youngkin, & Israel, 1996; O'Hara, Kiefer, Farrell, & Kemper, 
1998) and a number of plant extracts like green tea (Hasegawa, Yamda, & Mori, 
2003), garlic compounds (Elkayam, et. al., 2003) and conjugated linoleic acid 
(CLA)(Hargrave, et. al., 2002) were shown to possess either antidiabetic effects or 
have direct effects on adipose tissue. A large body of literature indicates that 
substantial progress has been made concerning our knowledge of bioactive 
components in plant foods and their links to obesity. Polyphenols constitute one of 
the ubiquitous groups of plant metabolites (Bravo, 1998) widely found in fruits, 
vegetables, cereals, legumes and wine (Aherne, O'Brien, 2002; Harborne, 1989).  
 A number of studies have been carried out to investigate the antiobesity 
effects of polyphenols like apigenin and luteolin (Han, et. al., 2003), kaempferol 
(Yu, et. al., 2006), myricetin and quercetin (Kwon, et. al., 2007),genistein and 
diadzein (Kim et. al., 2006; Naaz et. al., 2003; Dang & Lowik 2004),cyaniding 
(Tsuda, Ueno, Kojo, Yoshikawa & Osawa, 2005) grape seed proanthocyanidin 
extract (GSPE) (Preuss, et. al., 2000), xanthohumol (Nakagawa et. al., 2005) and 
epigallocatechin gallate (EGCG) (Wolfram et. al., 2006). Likewise, studies 
involving the effects on lipid metabolism have been carried out with carotenoids like 
fucoxanthin (Maeda et. al., 2005),coumarin derivatives like esculetin (Yang et. al., 
2006) and phytoalexins like resveratrol (Picard et. al., 2004). Other bioactive 
components of food with antiobesity effects include phytosterols, polyunsaturated 
fatty acids and organosulfur compounds. 
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2. PLANT PROFILE 
 
Fig-3. DELONIX ELATA 
Table - 1 : Scientific Classification 
Scientific Classification 
Kingdom            Plantae  
Phylum       Tracheophyta 
Class            
Magnoliopsida 
Order          Fabales 
Family  Leguminosae 
Genus  Delonix 
Species Elata 
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Table 2 
Vernacular names 
Tamil Vadanarayani 
Hindi  Sankasura, 
Gujrathi Sandesra  
Sanskrit Siddhesvara 
 
 
Habitat: 
Delonix elata has a widespread distribution and is found naturally between 
25 degrees north to 8 degrees south. Native countries Djibouti, Egypt, Ethiopia, 
Kenya, Saudi Arabia, Somalia, Sudan, Tanzania, United Republic of, Uganda, and 
Yemen. Introduced in Cambodia, Maldives, Myanmar, Namibia, Nigeria, Oman, 
Pakistan, and Sri Lanka. Present, but origin uncertain in India and Zambia. Also 
widely cultivated as an avenue tree and for shade elsewhere in the tropics. 
Description:  
Delonix elata is a perennial, medium-sized, deciduous tree about 2.5-15 m 
tall, with a spreading, rather rounded crown and very attractive, white fragrant 
flowers. Delonix elata is a variable species showing correlation with geography, 
variations mostly regarding number of pinnae pairs per leaf, and density of 
pubescence in the inflorescence (including the outside of the calyces). There are, 
however, good reasons for not recognizing these local or morphological forms as 
subspecies or varieties. This tree is a close relative of popular Delonix regia and has 
similar growth habit and characteristics, but differs from the latter in having small 
subulate deciduous stipules; white, yellow or orange petals which are only 1,6-3,8 
cm long; stamen-filaments which exceed the petals; and smaller pods, 13-26 cm 
long, 2,1-3,7 cm wide. 
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Chemical Constituents: 
The plant bark posessess  beta sitosterol,saponins, alkaloids, carotene.  
 
Medicinal properties:  
The leaf and bark extracts of D. elata are anti-inflammatory agents; a root 
decoction is drunk for abdominal pains. Leaves are reported to be used by traditional 
practitioners in cases of inflammatory joint disorders as a folklore remedy. A 
pychosomatic medicinal use relating to scorpion bite treatment is reported from 
India. Leaf and seed extracts have anti malarial and antiovicidal activity; hence these 
extracts are used by traditional practitioners to treat malaria. 
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LITERATURE REVIEW 
(Int J Pharm Pharm Sci, Vol 5, Suppl 4, 1-3). 
                  The objective of this review article is to highlight all the available 
information online or offline in the form of books or articles on Delonix elata (L.), 
one of most important medicinal plants. Methods: This article is a compiled report 
on medicinal properties and phytochemistry of D. elata based on the updated 
information collected from reviews, literature databases, research articles and books. 
Results: Delonix elata (L.) Gamble (Poinciana elata Linn.) commonly known as 
“white gul mohur” in English and is a reputed folklore remedy for arthritic disorders 
in many parts of Gujarat, India. The leaf extracts are anti-inflammatory agents. Root 
decoction of this plant is consumed for abdominal pains. Leaves are reported to be 
used by traditional practitioners for inflammatory joint disorders as a folklore 
remedy. Its pychosomatic medicinal use relating to scorpion bite treatment is also 
reported. The presence of phytochemicals such as alkaloids, tannins, triterpenoids, 
steroids and glycosides in the extracts of this plant supports its traditional uses as a 
potent medicinal plant for the treatment of various ailments. Conclusion: Scientific 
investigations are needed to be carried out on D. elata to bring such unexplored 
drugs into light to combat with various human diseases.  
 
Antioxidant activity: 
 
(Int J Pharm Pharm Sci, Vol 5, Suppl 4, 1-3). 
 
Ethanolic extract of Delonix elata is reported for its free radical scavenging 
property on different in vitro models, viz, 1,1-dipheny12-picrylhydrazine (DPPH), 
hydrogen peroxide, total antioxidant capacity and peroxy radical model. The in vitro 
lipid peroxidation (LPO) is also reported to be inhibited to a good extent by 
theethanolic leaf extract of Delonix elata [14,15]. The medicinalproperties of plants 
have been investigated in the recent scientificdevelopments throughout the world, 
due to their potentialantioxidant activities, no side effects and economic viability. 
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Themajority of the active antioxidant compounds flavonoids,isoflavones, flavones, 
anthocyanins, coumarins, lignans, catechins, 
and isocatechins. In addition to the above compounds found innatural foods, 
vitamins C and E, b-carotene, and a-tocopherol areknown to possess antioxidant 
potential [16-18].. 
ANTI-INFLAMMATORY ACTIVITY OF DELONIX ELATA. 
(Int J Pharm Pharm Sci, Vol 5, Suppl 4, 1-3). 
 
                    Delonix elata is known to be used for joint pains and in flatulence. It 
was accidentally observed that local people of some regions using the leaves and 
bark of Delonix elata in inflammation. There was n report on anti-inflammatory 
activity of Delonix elata. Antiinflammatory activity of the alcoholic extracts of the 
leaves and bark of Delonix elata was found to be significant. 
 
Anti-inflammatory activity of this plant is reported using carageenin induced 
oedema model [19-20]. The paw oedema was measured by using plethysmograph. 
The LD50 values of this plant extracts are reported as more than 100 mg/kg/b.w. in 
mice and the active principles in extracts are present usually in small quantities. A 
dose 300 mg/kg/b.w. was administered to assess the validity as known anti- 
inflammatory agent in comparison with phenylbutazone. The report indicates that 
the bark extract showed slight lower response than phenylbutazone (50 mg/kg). The 
leaf extract also showed significant anti-inflammatory action compared to control 
but it was lower than the effect of bark extract. Compounds like bioflavonoid are 
reported to produce anti-inflammatory action by decreasing capillary permeability 
[21]. Steroids are known to produce anti-inflammatory activity. The extracts tested 
might contain flavonoids/steriodis which resulted in producing antiinflammatory 
activity [22]. 
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Antibacterial activity:- 
 
(Int J Pharm Pharm Sci, Vol 5, Suppl 4, 1-3). 
 
The antibacterial activity of organic solvent extracts of this plant was 
determined by disc diffusion and broth dilution techniques against gram-positive 
bacterial strains (Bacillus subtilis, Staphylococcus aureus) and gram-negative 
bacterial strains (Escherichia coli, Klebsiella pneumoniae, Pseudomonas 
aeruginosa). The chloroform and methanol extracts exhibited significant 
antibacterial activity against gram-positive and gram-negative strains with minimum 
bactericidal concentration (MBC) ranging from 1.5 to 100 mg/ml. The presence of 
phytochemicals such as alkaloids, tannins, triterpenoids, steroids and glycosides in 
the extracts of these plants supports their traditional uses as medicinal plants for the 
treatment of various ailments. The observed antibacterial activity is attributed to the 
presence of bioactive compounds in the extracts of plants tested. The presence of 
these bioactive compounds in crude extracts is known to confer antibacterial activity 
against disease-causing microorganisms [23, 24] and offer protection to plants 
themselves against pathogenic microbial infections [25]. 
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3. AIM & OBJECTIVE 
The Goal of the present study is to investigate  
 Anti- hyperlipidemic activity of aerial parts of Delonix elata on high 
cholesterol diet induced hyperlipidemia in rats. 
The following objectives were set to achieve the goal of the present study 
1. To perform the phytochemical evaluation of ethanolic extracts of aerial parts 
of Delonix elata [EEDE]. 
2. To perform the acute toxicity studies of ehanolic extracts of Delonix elata on 
mice. 
3. To investigate the biochemical estimations of various doses of Delonix elata 
on lipid profile ( TC, TG, HDL, LDL, VLDL)  and kidney parameters urea, 
uric acid and creatinine in all the groups. 
4. To investigate the effect of various doses of Delonix elata on antioxidant 
enzymes (SOD, GSH and catalase) in all the groups 
5. Histopathology studies of heart. 
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4. PLAN OF WORK 
I. PHYTOCHEMICAL SCREENING: 
Collection: 
Collection of Delonix Elata. barks, authentication and shade drying. 
Extraction: 
Extraction of powdered barks with 70% ethanol. 
Preliminary Phytochemical examination for identification of chemical 
constituents. 
II. PHARMACOLOGICAL SCREENING: 
Acute oral toxicity study of ethanol extract of Delonix Elata.   (OECD 
Guideline 423). 
 Evaluation of Delonix Elata,.extract on lipid profile, kidney parameters 
urea, uric acid and creatinine and on antioxidant enzymes (SOD, GSH and catalase) 
in all the groups. 
Parameters Considered for evaluation. 
Lipid Profile: 
Serum Cholesterol 
Triglycerides 
High Density Lipoprotein 
Low Density Lipoprotein 
Very Low Density Lipoprotein 
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Kidney parameters: 
Urea 
 Uric acid 
Creatinine 
Antioxidant enzymes:  
 Superoxide Dismutase (SOD) 
 Glutathione (GSH) 
 Catalase 
Histopathological examination of Heart 
Statistical Analysis: 
4.2. Methods 
Identification, collection and authentication of plant material: 
 The aerial parts of Delonixelata were collected from tirumala hills belong to 
Thirupathi, Andhra Pradesh, India. in the year of 2016 (May). 
 The plant specimen was authenticated by Professor P. Jayaraman. Ph.D., 
founder of  Plant Anatomy Research Centre, (PARC). Tambaram, Chennai.  After 
cleaning    parts of plant from foreign particles they spread over trays and separately 
dried in shade, pulverized by a mechanical grinder and passed through 40-mesh 
sieve to get the fine powder, finally subjected to extraction.  
 
 
 
35 
 
 
 
Ethanolic extraction of aerial parts of Delonixelata 
Introduction 
 The commonly employed technique for the separation of the active 
constituents from the crude drug is called extraction which involves the use of 
different solvents. Many of the complex substances metabolized by the plants have 
therapeutic importance. But these are always found in association with other 
substances. Therefore in order to study these active constituents alone it has to be 
separated from other unwanted substances produced. 
Preparation of extract: 
 The aerial parts of Delonixelatawere collected, washed, dried in shade and 
pulverized in a grinder- mixer to obtain a coarse powder and then passed through 40 
mesh sieves. The powdered drug was subjected to solvent extraction by soxhlet 
apparatus.  
Extraction procedure: 
 About 100g of powdered drug was extracted successively with 70% ethanol 
using soxhlet apparatus. The extraction was carried out for 72 hours until the extract 
becomes colourless. Then the solvent was completely removed by evaporating in 
rotatory flask evaporator. The dried extract thus obtained was kept in refrigerator 
until the further experiment.    
Percentage yield: 
 Percentage yield of 100gms of etahnolic extract of aerial parts 
ofDelonixelatawas found to be 14.6% w/w. 
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I. Preliminary photochemical screening: 
 The Ethanolic extract of aerial parts of Delonixelata(EEDE) was subjected to 
preliminary phytochemical screening for the detection of various phytochemical 
constituents such as carbohydrates, alkaloids, saponins, phenolic compounds, gums, 
tannins and flavoniods.  
 The detailed study about the phytochemical test procedure as follows   
A. Test for carbohydrates: 
 A small quantity of extracts was dissolved separately in distilled water and 
filtered. The filtrate was subjected to following tests 
Molisch’s test: 
            Take 2-3 ml of extract add 1ml of freshly prepared α-naphthol solution in 
alcohol shake and add conc.H2SO4 from sides of the test tube under tap water. Violet 
ring is formed at the junction of two liquids. 
Benedict’s test:  
             Take test solution and add benedicts reagent and heated on water bath and 
color was formed. 
Fehling’s test: 
           Take 1ml of extract add equal quantity of Fehling’s solution A and B heat in 
boiling water bath for 5-10 minutes. Brick red precipitate is formed.    
Barfoed’s test:  
             Take 1ml of test solution add 1ml of Barfoed’s reagent and heated on water 
bath. Red precipitate was formed. 
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B. Test for tannins 
Colour reaction: 
Tannins give color reactions with iron. 
Catechol solution + Iron salts               Green fluorescence 
Condensed tannins + Iron salts              Green fluorescence 
Gallic acid + Iron salts             Blue fluorescence 
Ellagic acid + Iron salts             Blue fluorescence 
Matchstick test:  
 Dip matchstick in plant extract. Dry it. Moisten it with hydrochloric acid and 
warm near flame. Wood will turn pink or red in color due to phloroglucinol. 
Gelatin test: 
 Solution of tannin (0.5% - 1%) precipitates 1% solution of gelatin containing 
10% sodium chloride. 
Phenazone test: 
 Take 5ml of aqueous extract of drug. Add 0.5 g of sodium acid phosphate. 
Warm it and cool, then filter solution. To the filtrate, add 2% solution of phenazone. 
Tannins will be precipitated. Precipitates will be bulky and colored. 
Gold beater’s skin test: 
 Soak a small piece of gold beater’s skin in 2% hydrochloric acid. Rinse it 
will distilled water. Place it in solution to be tested for 5 minutes. Wash in water and 
transfer to 1% solution of ferrous sulphate. Black or brown color of skin indicates 
presence of tannins. 
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Catechin test:  
 Catechin when heated with acid produce phloroglucinol. Phloroglucinol can 
be detected with matchstick test. (Kokate et al.,2006 and khandelwal, 2006) 
C. Test for alkaloids: 
Dragendroff’s test:  
Add Dragendroff’s reagent (potassium bismuth iodide solution) to the 
extract. Orange red precipitate is formed. 
Mayer’s test: 
              Take 1 ml of extract add 1ml of Mayer’s reagent (potassium mercuric 
iodide). Cream coloured precipitate is formed. 
Hager’s test: 
              Take 1 ml of extract add 3 ml of Hager’s reagent (saturated aqueous 
solution of picric acid). A yellow coloured precipitate indicates the presence of 
alkaloids. 
Wager’s test: 
             Take 1 ml of the extract add 2 ml of Wager’s reagent (iodine in potassium 
iodide) formation of reddish brown precipitate indicates the presence of alkaloids. 
G. Test for indole alkaloids 
Van-Urk’s test: 
              Take test sample and add para-dimethyl amino benzaldehyde. Blue colour 
formed. 
 
 
39 
 
 
 
D. Test for saponins: 
Foam test: 
 Take small quantity of ethanolic extract add 20 ml of distilled water, shaken 
in a graduated cylinder for 15 minutes, 1 cm layer of foam develops. 
Hemolytic test: 
           Take drug extract or dry powder to one drop of blood, Placed on the glass 
side. Hemolytic zone appears. 
D. Test for flavonoids: 
Shinoda test: 
           Take ethanolic extract of powder add magnesium turnings or foil and add 
conc.Hcl. Intense cherry red colour or orange red colour is formed. 
General tests: 
     To small quantity of residue, add lead acetate solution. Yellow color precipitate is 
formed. 
a) Addition of increasing amount of sodium hydroxide to the residue shows 
yellow coloration, which decolorizes after addition of acid. 
E. Test for gums: 
 Mucilage test: 
 Take 10 ml of aqueous extract and add slowly to 25 ml of absolute alcohol 
with constant stirring. Filtered the precipitate and dried in air. Examine the 
precipitate for its swelling properties and for the presence of carbohydrates. 
Hydrolytic test: 
               Hydrolyze the test solution using dilute Hcl. Perform Benedict’s and 
Fehling’s test. Red colour is formed.    
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F. Test for fixed oils and fats: 
Spot test: 
              Press a small quantity of extract between the filter paper. Oil stains on the 
paper indicates fixed oils. 
Saponification test: 
             Take 1 ml of the extract add few drops of 0.5N alcoholic KOH and drop of 
phenolphthalein. Heat the mixture on water bath for 1-2 hours. Formation of soap or 
partial neutralization of alkali. 
G. Test for acidic compounds: 
          To the extract add NaHCO3 solution. Effervescence is observed. 
          To the extract add water and warm, filter. Litmus paper turns to blue colour 
H. Test for amino acids: 
Ninhydrin test: 
 Take small quantity of extract add 2 drops of freshly prepared 0.2% 
Ninhydrin reagent (0.1% solution in n-butanol). Heat for few minutes, blue colour is 
formed. 
Biuret test: 
 Take 1 ml of 40%NaOH solution and 2 drops of 1% copper sulphate 
solution, add 1ml of extract. Blue colour is formed. 
Xanthoproteic test: 
 Take test solution and add 1 ml of conc. nitric acid and boil. Yellow 
precipitate is formed. After cooling add 40% sodium hydroxide solution orange 
colour is formed. 
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Trytophan test: 
 Take 3 ml of test solution, a few drops of glyoxalic acid and conc.H2SO4. 
Reddish violet appears at the junction of two layers. 
Cysteine test: 
 Take 5 ml of test solution add few drops of 40%NaOH and 10% lead acetate 
solution. Boil precipitate of lead sulphate is formed. 
Millon’s test: 
 Take 3 ml of test solution, mix with 5 ml of Millon’s reagent. White ppt, 
warm ppt. turns brick red or the ppt. dissolves giving red colour solution, indicates 
the presence of tyrosine. 
II. Acute toxicity studies 
Experimental Animals: 
 Swiss albino mice (20-25gm) and Wistar albino rats (120-125gm) of male 
rats were purchased from Sri Venkateshwara Enterprises, Hyderabad, India. All 
animals were maintained in an air-conditioned room at 25°C±2°C, with a relative 
humidity of 75%±5%, and a 12-h light/dark cycle. A basal diet and tap water were 
provided ad libitum. Male and female rats were assigned to each dose group by 
stratified random sampling based on body weight. The animals were kept under 
laboratory conditions for an acclimatization period of 7 days before carrying out the 
experiments.  
Experimental procedure: 
 Male albino mice weighing 20-25gm were used for the study. The starting 
dose level of EEDE . Baker was 5, 50, 300, 2000 and 5000 mg/kg body weight p.o. 
Dose was administered to overnight fasted mice’s. Food was withheld for a further 
3-4 hours after administration of Delonixelataand observed for signs for toxicity. 
The body weight of the mice’s before and after administration were noted that 
changes in eyes and mucous membranes, skin and fur, respiratory, circulatory, 
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autonomic, and central nervous systems, and also motor activity and behavior 
pattern. Special attention was directed to observations of convulsions, tremors, 
diarrhea, salivation, lethargy, sleep, and coma were noted. The onset of toxicity and 
signs of toxicity of LD50 values are noted. 
II. Pharmacological screening of hyperlipidemic activity: 
Cholesterol 
 
 Cholesterol literally means “solid alcohol from bile”. Cholesterol and 
triglycerides are two forms of lipid/fat. Cholesterol is made primarily in the liver 
(about 1,000 mg per day), but it is also created by cells lining the small intestine and 
by the individual cells in the body. 
 Cholesterol and other fats cannot dissolve in blood. They have to be 
transported to and from the cells by special carriers called “lipoproteins”. Important 
lipoproteins are LDL and HDL. 
 The enzymes involved in the cholesterol synthesis are found in the cytosol 
and microsomal fractions of the cell. Acetate to acetyl Co A provides all the carbon 
atoms in the cholesterol. Cholesterol synthesis takes place in 5 stages, which 
includes synthesis of HMG CO A, formation of mevalonate (6c), production of 
isoprenoid units (5c), synthesis of squalene (30c) and conversion of squalene to 
cholesterol (27c). 
 Cholesterol biosynthesis is controlled by the rate-limiting enzyme HMG 
CoA reductase, at the beginning of the pathway, which is found in association with 
endoplasmic reticulum and subjected to different metabolic controls like feedback 
control, hormonal regulation, inhibition by drugs and inhibition by bile acids. 
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Mechanism of action:  
 Biosynthesis of cholesterol is directly regulated by the cholesterol levels 
present, though the homeostatic mechanisms involved are only partly understood. A 
higher intake from food leads to a net decrease in endogenous production, whereas 
lower intake from food has the opposite effect. The main regulatory mechanism is 
the sensing of intracellular cholesterol in the endoplasmic reticulum by the protein 
SREBP (sterol regulatory element-binding protein 1 and 2). In the presence of 
cholesterol, SREBP is bound to two other proteins: SCAP (SREBP cleavage 
activating protein) and Insig1. When cholesterol levels fall, Insig-1 dissociates from 
the SREBP-SCAP complex, which allows the complex to migrate to the Golgi 
apparatus. Here SREBP is cleaved by S1P and S2P (site-1 and -2 protease), two 
enzymes that are activated by SCAP when cholesterol levels are low. The cleaved 
SREBP then migrates to the nucleus, and acts as a transcription factor to bind to the 
sterol regulatory element (SRE), which stimulates the transcription of many genes. 
Among these are the low-density lipoprotein(LDL) receptor and HMG-CoA 
reductase. The LDL receptor former scavenges circulating LDL from the 
bloodstream, whereas HMG-CoA reductase leads to an increase of endogenous 
production of cholesterol. Then, cholesterol can be filled in arteries which leads to 
plaque formation and causes insufficient supply of oxygen, B.P increases leads to 
coronary heart diseases. [American heart association] 
Causes: 
High cholesterol and other lipid disorders can be inherited (genetic) or associated 
with: 
 Fatty diets  
 Diabetes, hypothyroidism, Cushing's syndrome, and kidney failure 
 Certain medications, including birth control pills, estrogen, corticosteroids, 
certain diuretics, and beta-blockers  
 Lifestyle factors, including habitual, excessive alcohol use and lack of 
exercise, leading to obesity. 
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 People who smoke and also have high cholesterol are at even greater risk for 
heart disease. Lipid disorders are more common in men than women. 
Rosuvastatin: 
 
 
Systematic (IUPAC) name:- 
 (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-
(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid. 
 
Rosuvastatin (marketed by AstraZeneca as Crestor) is a member of the 
drug class of statins, used in combination with exercise, diet, and weight-loss to treat 
high cholesterol and related conditions, and to prevent cardiovascular disease. The 
primary uses of rosuvastatin is for the treatment of dyslipidemia. It is recommended 
to be used only after other measures such as diet, exercise, and weight reduction 
have not improved cholesterol levels. Like all statins, rosvastatin works by 
inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key 
role in production of cholesterol in the body. 
Mechanism of action: 
 Rosuvastatin inhibits cholesterol synthesis via the mevalonate pathway by 
inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-
CoA reductase is the enzyme responsible for the conversion of HMG-CoA to 
mevalonic acid, the rate-limiting step of cholesterol synthesis by this pathway. The 
active form of statins bears a chemical resemblance to the reduced HMG-CoA 
reaction intermediate that is formed during catalysis. Structure-activity relationship 
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studies have demonstrated that statins bind to HMG-CoA reductase at the same site 
as the reduced intermediate and are held in place by similar chemical interactions. 
Unlike Lovastatin and simvastatin, which undergo in vivo hydrolysis to their active 
form rosuvastatin is synthetically produced in active form. Cholesterol biosynthesis 
accounts for approximately 80% of cholesterol in the body; thus, inhibiting this 
process can significantly lower cholesterol levels [Reszka, A.A et al., 2003 and 
Schmidt, E.B et al., 2004]. 
Dyslipidemia: 
 Hypercholesterolemia and mixed dyslipidemia to reduce 
total cholesterol, LDL-C, apo-B, triglycerides levels, and CRP as well as 
increase HDL levels. 
 Heterozygous familial hypercholesterolemia in pediatric patients 
 Homozygous familial hypercholesterolemia 
 Hypertriglyceridemia (Fredrickson Type IV) 
 Primary dysbetalipoproteinemia (Fredrickson Type III) 
 Combined hyperlipidemia 
Pharmacokinetics: 
Absorption: In clinical pharmacology studies in man, peak plasma concentrations 
of rosuvastatin were reached 3 to 5 hours following oral dosing. Both Cmax and AUC 
increased in approximate proportion to CRESTOR® (rosuvastatin calcium) dose. 
The absolute bioavailability of rosuvastatin is approximately 20%. Administration of 
CRESTOR with food did not affect the AUC of rosuvastatin. The AUC of 
rosuvastatin does not differ following evening or morning drug administration. 
Distribution: Mean volume of distribution at steady-state of rosuvastatin is 
approximately 134 liters. Rosuvastatin is 88% bound to plasma proteins, mostly 
albumin. This binding is reversible and independent of plasma concentrations.  
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Metabolism: Rosuvastatin is not extensively metabolized; approximately 10% of a 
radiolabeled dose is recovered as metabolite. The major metabolite is N-
desmethylrosuvastatin, which is formed principally by cytochrome P450 2C9, and in 
vitro studies have demonstrated that N-desmethylrosuvastatin has approximately 
one-sixth to one-half the HMG-CoA reductase inhibitory activity of the parent 
compound. Overall, greater than 90% of active plasma HMG-CoA reductase 
inhibitory activity is accounted for by the parent compound.  
Excretion: Following oral administration, rosuvastatin and its metabolites are 
primarily excreted in the feces (90%). The elimination half-life (t1/2) of rosuvastatin 
is approximately 19 hours. After an intravenous dose, approximately 28% of total 
body clearance was via the renal route, and 72% by the hepatic route. 
Contraindications: 
 Rosuvastatin has multiple contraindications, conditions that warrant 
withholding treatment with rosuvastatin, including hypersensitivity to rosuvastatin 
or any component of the formulation, active liver disease, and elevation of serum 
transaminases, pregnancy, or breast-feeding. Rosuvastatin must not be taken while 
pregnant as it can cause serious harm to the unborn baby. In the case of 
breastfeeding, it is unknown whether rosuvastatin is passed through breastmilk, but 
due to the potential of disrupting the infant's lipid metabolism, patients should not 
breast feed while on rosuvastatin. 
Adverse effects: 
o Constipation, Heartburn, Dizziness, Insomnia, Depression, Joint pain, Memory 
loss or forgetfulness, Confusion 
 The following rare adverse effects are more serious. Like all statins, 
rosuvastatin can possibly cause myopathy, rhabdomyolysis 
o Muscle pain, tenderness, or weakness, Lack of energy, Fever, Nausea, 
Extreme tiredness, Weakness, Unusual bleeding or bruising, Loss of appetite 
 If any signs of an allergic reactions  
o Rash, Itching, Difficulty breathing or swallowing, Swelling of the face, throat, 
tongue, lips, eyes, hands, feet, ankles, or lower legs, Numbness or tingling in 
fingers or toes. 
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IV. Methodology: 
 Animals:  
 Healthy male wistar albino rats were procured from animal house of Sri 
Venkateshwara Enterprises, Hyderabad, India and weigh about 120-125gms were 
used for the study. Every experimental animal was clinically examined pre-
operatively for any disease. The animals were kept under observation in laboratory 
and allowed acclimatize, for 7 days before experimentation. Animals kept in 
separate spacious clean cages under controlled room temperature (25±1)°c & 
relative humidity (50±15)%; in a 12hrs light-dark cycles. They fed with a standard 
diet and water ad-libitum. Before the experiment the rats were divided into groups  
GROUPS: 
Group I: Control (Normal control) 
Group II : Positive control (5% cholesterol diet for 3months) 
Group III: Standard (5% cholesterol diet + ROSVASTATIN (20mg/kg) ) 
Group IV : Test I (Plant Extract-250mg/kg b wt of EEDE+ 5% cholesterol 
diet) 
Group V  : Test II (Plant Extract-500mg/kg b wt of EEDE+ 5% cholesterol 
diet) 
PROCEDURE: 
 Rats were divided into five groups each group contain six animals. Group I 
serves normal which receives normal saline (5ml/kg b wt) for last 28 days orally; 
Group II serves as positive control which receives 5% cholesterol diet for 3 months 
continuously; Group III serves as standard which receives Rosavastatin (20mg/kg b 
wt; I.P route) for last 28 days and Group IV, Group V serves as test which receives 
EEDE  at dose of 250 and 500 mg/kg b wt, through oral route throughout the study 
period and also receives 5% cholesterol diet for last 28 days. After the study period 
animals were sacrificed by collecting blood through cardiac puncture and collected 
blood was centrifuged and serum was collected and biochemical analysis were 
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performed lipid profiles for serum levels TC, TG, HDL, LDL, VLDL, Urea, 
Creatinine, uric acid and antioxidant studies SOD, GSH and Catalase. 
Estimation of weight gain: 
 During the experimental period, the high cholesterol diet consumed and 
weight gained by rats was recorded on 0th, 14th and 28th day of EEDE treatment. The 
pre-weighed food pellets (approximately 30g) were placed inside the hopper of the 
cage. The food consumed by individual rat was quantified by weighing leftover food 
in the hopper (Kokate et al., 2006). 
 
Estimation of total cholesterol (TC): (CHOD-PAP Method) 
 The reagents kits intended for the in-vitro quantitative determination of 
cholesterol in serum/plasma. 
Principle: - The cholesterol esters are hydrolysed by enzyme cholesterol esterase to 
give free cholesterol and fatty acid molicules. This free cholesterol gets oxidised in 
presence of cholesterol oxidase to liberate cholset 4en-3one and H2O2. Liberated 
H2O2 by this reaction combines with phenol and 4 amino antipyrine in presence of 
peroxidise to form red colourquinonimine complex, the intensity of which is 
measured at 505 nm. (490-530nm) it is directly proportional to the cholesterol conc. 
Present in sample. 
General system parameters:- 
Wave length  : 505 nm (490-530nm) 
Incubation  : 5 min  
Sample volume : 10µl 
Reagent volume : 1.0ml 
Standard concentration: 200mg/dl 
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Procedure:- 
Bring all the reagents of assay to room temperature. 
 Procedure for 1ml Procedure for 3ml 
 B S T B S T 
Enzyme 
reagent 
1 ml 1 ml 1 ml 3 ml 3 ml 3 ml 
Standard - 10µl - - 30µl - 
Sample - - 10µl - - 30µl 
 Mix well and incubate for 5 min at room temperature. Mix well and measure 
the absorbance of standard and test against the reagent blank at 505 nm. (490-
530nm) 
 
Calculation:- 
   Total cholesterol mg/dl = Abs TC/Abs STD ×200 
 
Estimation of triglycerides (TG):(GPO- Method) 
 Diagnostic kit was used for estimation of triglycerides, which followed end 
point colorimetry enzymatic test using glycerol-3-phosphate oxidase.  
Principle:  The enzyme, lipoprotein lipase catalyzes hydrolysis of TGs to glycerol 
and FAs. Glycerol then is phosphorylated in an ATP - requiring reaction catalyzed 
by glycerophosphate. The formed glycerophosphate is oxidized to dihydroxyacetone 
and H2O2in a glycerophosphate oxidase (GPO) catalyzed reaction. H2O2then reacts 
with 4 -AAP and 4 - chlorophenol under the catalytic influence of peroxidase to 
form colouredquinoneimine complex, the intensity of which was measured at 505nm 
(Venkatesh G1 et al., 2010). 
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     Lipase  
        Triglyceride + 3H
2
O                                 Glycerol + 3 fatty acids  
Glycerokinase 
         Glycerol + ATP                                Glycero –3-phosphate + ADP 
Glycerophospate oxidase  
Glycero –3-Phosphate + O
2                                                        
DHAP + H
2
O
2  
Reagents used:  
Sl. No. Reagent composition Conc. in the final test mixed 
1. Pipes butter 50mmol/l 
2. 4-Chlorophenol 5mmol/l 
3. Mg
2+
 
5 mmol/l 
4. ATP 1 mmol/l 
5. Lipase >5000 U/l 
6. Peroxidase >1000 U/l 
7. Glycerol Kinase >400 U/l 
8. Glycerol - 3- phosphate 
oxidase 
>4000 U/l 
 
Standard: The concentration of standard triglyceride used was 200mg/dl  
Assay & Procedure: Fresh clear and unhaemolysed serum was used for the 
estimation.  
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Reaction parameters: 
1 Reaction type End point 
2 Wave Length 505 nm 
3 Optical length 1 Cm 
4 Temperature 37
0
C 
5 Measurement Against reagent blank 
Summary of assay details: 
Pipetted in to test tube Blank Standard Test 
Reagent 1000 μl 1000 μl 1000 μl 
Standard - 10 μl - 
Sample - - 10 μl 
 The reaction mixtures were mixed well and incubated for 10 min at 37
0
C. 
The absorbance of sample and standard were measured against reagent blank at 505 
nm. 
Calculations:- 
Abs of test 
Serum triglycerides (mg/dl) =                           × Conc of standard 
Abs of STD 
 
Estimation of high-density lipoprotein cholesterol (HDL-C): 
 Diagnostic kit was used for estimation of HDL cholesterol, which followed 
Cholesterol oxidase / peroxidase (CHOD-POD) method.  
Principle: HDL-C is measured in the supernatant after the precipitation of the 
lipoproteins including chylomicrons, very low-density lipoproteins (VLDL), low-
density lipoproteins, intermediate-density lipoproteins directly from serum 
polyanions like phosphotungstic acid and along with MgCl2are added to an aliquot 
of serum an immediate heavy precipitation is formed. The precipitate then is 
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sedimented by centrifugation and HDL cholesterol is measured in the clear 
supernatant, which is estimated by enzymatic method as described earlier in 
estimation serum of TC (VenuPamidiboina et al., 2010). 
Reaction parameters: 
1 Reaction type End point 
2 Wavelength 505 nm 
3 Optical path 1 cm 
4 Temperature 37
0
C 
5 Measurement Against reagent blank 
Preparation:- 
 Take 0.5 ml of serum /plasma in to glass tube. Add 50 µl precipitating 
reagent. Mix well, leave it at R.T. For 10 min. centrifuge at 3000 r.p.m. for 10 min. 
take the clean supernatant for HDL cholesterol estimation. 
Procedure:- 
 B S T 
Enzyme reagent 1 ml 1 ml 1 ml 
Standard - 0.01 ml - 
Supernatant sample - - 0.01 ml 
    Mix well and incubate for 5 min at 37°c. Measure the absorbance of HDL&std at 
510 nm. 
Calculations: - HDL cholesterol mg/dl = Abs TH/Abs STD×200 
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Estimation of creatinine: 
Method: Jaffe’s method 
Principle: Creatinine reacts with alkaline picrate to produce an orange-yellow 
colour (the jaffe’s reaction).The absorbance of orange-yellow coloured complex 
formation is directly proportional to the creatinine concentration and is measured 
photo metrically at 500-520 nm (Bowers LD et al., 1980; Bartels H et al., 1972) 
Reagents: 
1. Picric acid reagent            100ml 
2. Alkaline buffer reagent     100ml 
3. Standard creatinine           10ml 
4. Acid reagent                      10ml 
Procedure: Set the Auto-analyser instrument with parameters given along with the 
kit. Prepare the working. Standard, test solution as per the protocol. Mix well and 
read initial absorbance (A0) 20 seconds after mixing and final absorbance (A1) 80 
seconds after mixing at 505 nm. 
General properties: 
Reaction type Kinetic with standard 
Wave length 520nm (green filter) 
Incubation temperature Room temperature 
Incubation time 30 sec 
Read time 60 sec 
No. of readings 2 
Linearity  20 mg% 
Sample volume 100µL 
Reagent volume 1µL 
Cuvette 1cm light path 
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Laboratory procedure: 
 Blank Standard Sample 
Working reagent 1ml 1.0 ml 1.0 ml 
Standard _ 0.1ml _ 
Sample _ _ 0.1ml 
 
 Mix well and allow it to stand for 5 mins. Read absorbance for absorbance 
for standard and sample against distilled water at 520nm against blank. 
 For test ∆AT= A1T-A0T 
 For standard ∆AS= A1S-A0S  
  ∆AT 
Calculations: 
∆AS 
Estimation of urea: 
Principle: 
 Urease catalyses the conversion of urea to ammonia and carbon dioxide. The 
ammonia released reacts with a mixture of salicylate, hypochlorite and nitropruside 
to yield a blue-green coloured compound (indophenols). The intensity of colour 
produced is proportional to the concentration of urea in the sample and is measured 
photometrically at 570nm or with yellow filter (Chaney AL et al., 1962). 
Urea + H20                    2NH3 + CO2 
    urease 
Reagents: 
Urease reagent         50ml 
Enzyme concentrate 1 vial 
Colour reagent            50ml 
Urea standard             2ml 
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General system parameters 
Mode of reaction End point 
Wave length 570nm 
Temperature Room temperature 
Standard concentration 40mg% 
Linearity 300mg/% 
Blank Reagent 
Incubation time 10min 
Cuvette 1cm light path 
 
Laboratory procedure 
 Blank Standard Sample 
Working reagent 1000µL 1000µL 1000µL 
Standard _ 10µL _ 
Sample _ _ 10µL 
  
Mix and incubate for 5minutes at room temperature. Read the absorbance of 
the standard and sample against reagent blank. 
 
Calculations: 
a) Urea concentration mg        =        Absorbance of sample   × 40 (stdconc)                               
     Absorbance of Standard  
 
b) Blood Urea Nitrogen in mg% =   a  × 0.467 
Estimation of uric acid: 
Principle: 
Uric acid + O2+2 H20            llantoine + CO2 + H2O2 
Uricase 
2H2O2+ ESPAS+4-AAP                   Purple Quinoeimine + 4 H2O2 
 
Reagents: 
Enzyme reagent          50ml 
Standard                     2ml 
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General system parameters 
Mode of reaction End point 
Wave length 546nm 
Reaction slope Increasing 
Temperature Room temperature 
Standard concentration 5mg% 
Linearity 25mg/% 
Blank Reagent 
Reagent volume 1ml 
Incubation time 10min 
Cuvette 1cm light path 
 
Laboratory procedure 
 Blank Standard Sample 
Enzyme Reagent 1000µL 1000µL 1000µL 
Standard _ 10µL _ 
Sample _ _ 10µL 
 
 Mix and incubate for 5minutes at room temperature. Read the absorbance of 
the standard and sample against reagent blank (Fossati et al., 1980, Tietz NW et al., 
1995, Vassault A et al., 1986). 
Calculations: 
Uric acid mg/dl              =         Absorbance of sample   × 5 (stdconc) 
   Absorbance of Standard  
Estimation of superoxide dismutase (SOD): 
           Known amount of tissue was weighed and washed in ice cold saline and 
homonized in ice cold 0.1M TrisHcl buffer for estimations.  
           The assay of SOD was based on the ability of SOD to inhibit spontaneous 
oxidation of adrenaline to adrenochrome. 0.05 ml supernatant was added to 2.0 ml 
of carbonate buffer and 0.5 ml of 0.01mM EDTA solution. The reaction was 
initiated by addition of 0.5 ml of epinephrine and the autooxidation of adrenaline 
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(3× 10-4 M) to adrenochrome at pH 10.2 was measured by following change in OD 
at 480 nm. The change in optical density every minute was measured at 480 nm 
against reagent blank. The results are expressed as units of SOD activity (mg/wet 
tissue). One unit of SOD activity induced approximately 50% inhibition of 
adrenaline. 
Estimation of catalase activity (CAT): 
 Catalase activity was determined spectrophotometrically according to 
previously published method. Briefly, to 1.95ml of 10mM H2O2 in 60mM phosphate 
buffer (pH=7.0), 0.05ml of the liver homogenate was added and rate of degradation 
of H2O2 was followed at 240nm per min. Catalase content in terms of U/mg of 
protein was estimated from the rate of decomposition of H2O2 using the formula 
k=2.303/ Δt × log (A1/A2) s-1 (A unit of catalase is defined as the quantity which 
decomposes 1.0 µmole of H2O2 per min at pH=7.0 at 25oC, while H2O2 
concentration falls from 10.3 to 9.2 mM) [prabakar KR et al., 2006]. 
Estimation of glutathione (GSH): 
 The assay is based on the formation of a relatively stable yellow product 
when sulphydryl groups react with DTNB. Briefly, proteins were precipitated using 
10% TCA, centrifuged and 0.5 ml of the supernatant was mixed with 0.2M 
phosphate buffer (pH 8.0) and 10mM DTNB. This mixture was incubated for 10 
min and the absorbance was measured at 412nm against appropriate blanks. The 
glutathione content was calculated by using the standard plot under same 
experimental conditions. Plotting the absorbance against GSH concentration (0.005-
0.042 µmoles) gave the standard curve. A linear correlation coefficient (r2 = 0.999) 
was obtained [Moran A et al., 1979]. 
4.3 Histopathological studies: 
             The tissues were washed immediately with saline and then fixed in 10% 
formalin solution. After fixation, the heart tissues were processed in alcohol- xylene 
series and then embedded in paraffin. The serial sections were cut and each section 
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was stained with hematoxylin and eosin. The slides were examined under 
microscope and photographs were taken. 
4.4Statistical analysis: 
 The result were expressed as mean ± SD and analyzed statistically using one 
way ANOVA followed by Dunnet test, Data were computed for statistical analysis 
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5. MATERIALS AND METHODS 
5.1. Materials 
Table3: List of chemicals 
S.NO Chemical Manufacture 
1 Cholesterol Mathri Laboratories Pvt. Limited 
2 Rosuvastatin Ranbaxy 
3 Formalin Sd-fine chem.. Limited 
4 Cholesterol kit Span diagnostics 
5 Triglyceride kit Span diagnostics 
6 HDL kit Span diagnostics 
7 Urea kit Span diagnostics 
8 Creatinine kit Span diagnostics 
9 Uric acid kit Span diagnostics 
10 Antioxidant studies kit Span diagnostics 
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List of equipments 
Table5: List of equipment 
S.NO Equipment Manufacture 
1. Semi auto analyser  
(CL380 biochemistryanalyser) 
Elico 
2. Laboratory Centrifuge (R-8c) Remi  
3. Micropipette  Thermo scientific 
4.  Junior Grindwell J.U.C. Mumbai 
 
The Present study was designed to assess the anti- hyperlipidemic activity of 
Delonix Elata.on high cholesterol diet induced hyperlipidemia in rats and the work 
was carried out using the methods described below: 
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6. RESULTS 
6.1. Extract: 
Table-6: Ethanolic extract of aerial parts of Delonix elata shows yield, colour, 
nature. 
S.NO EXTRACT RESULT 
1 YIELD 13.5% 
2 COLOUR Yellowish brown 
3 NATURE Semisolid 
 
6.2. PHYTOCHEMICAL ANALYSIS: 
       The preliminary phytochemical analysis revealed the presence of 
carbohydrates, alkaloids, flavonoids, tannins, steroids, saponins, proteins, gums and 
phenolic compounds in ethanolic extract of aerial parts of Delonix elata 
Table-7: Preliminary Phytochemical analysis of ethanolic extract aerial parts of 
Delonix elata (Consolidated Repord) 
S.NO COMPOUNDS EEDE 
1 Carbohydrates + 
2 Alkaloids + 
3 Glycosides + 
4 Fixed oils - 
5 Flavonoids + 
6 Tannins + 
7 Steroids + 
8 Phenolic compounds + 
9 Amino acids - 
10 Saponins + 
11 Gums + 
12 Proteins + 
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+: presence of compounds 
-: absence of compounds 
6.3. ACUTE TOXICOLOGICAL STUDY 
 The acute toxicity of the EEDE was carried out and the results are tabulated 
below according to procedure was followed by using OECD 423 (Acute Toxic Class 
Method). 
Table -8: Acute toxicity studies of EEDE 
S.NO Groups Dose/kg 
(body 
weight) p.o 
Signs of 
Toxicity 
Onset of 
Toxicity 
Duration 
of Study 
1 EEDE 5mg No signs of 
Toxicity 
Nil 14 days 
2 EEDE 50mg No signs of 
Toxicity 
Nil 14 days 
3 EEDE 300mg No signs of 
Toxicity 
Nil 14 days 
4 EEDE 2000mg No signs of 
Toxicity 
Nil 14 days 
5 EEDE 5000mg No signs of 
Toxicity 
Nil 14 days 
 
 The therapeutic dose was calculated as 1/10th of the lethal dose for the 
purpose of antihyperlipidemic activity. The dose of EEDE was further reduced to 
2000 mg/kg and observed for 14 days. This particular dose was found to be safe and 
no toxicity was observed. One-tenth of the upper limit dose was selected as 250 
mg/kg b.wt for test group. The LD50 value determined by the method 423 as per 
guidelines of Organization for Economic Co-operation Development (OECD) was 
found to be 5000mg/kg b.w. by oral route of EEDE which show no toxicity at this 
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particular dose. Therefore, 1/10 and 1/20 of lethal dose has been selected for the 
experiment. i.e 250 mg and 500 mg/kg    
 
6.4. HYPERLIPIDEMIA ACTIVITY: HIGH CHOLESTEROL 
DIET INDUCED HYPERLIPIDEMIC ACTIVITY 
TABLE-9: Effect of EEDE on weight gain in hyperlipidemia-induced rats for 12 
weeks. 
Parameter Test group Day 0  14th day 28th day 
 
 
Weight gain 
Normal control 
 
Positive control 
 
Standard  
 
EEDE250mg/kg 
 
EEDE500mg/kg 
124.7±3.10 
 
213.5±7.00 
 
198.3±4.79*** 
 
203.5±5.36* 
 
191.3±3.78*** 
126± 3.36 
 
226.8±8.21 
 
173.3± 5.03*** 
 
189±7.05*** 
 
174.2±4.68*** 
126.5± 3.12 
 
237.8±7.22 
 
154±4.55*** 
 
173.7±5.01*** 
 
165±4.87*** 
 
Values are expressed as mean ± SD (n=6).Values were significant when 
compared with cholesterol group. * P<0.05, ** P<0.01, ***P<0.001 (one way 
ANOVA followed by Dunnett test) 
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Graph I 
 
  
Effect of EEDE on weight gain in cholesterol induced rats. 
Values are expressed in Mean± SD for six animals. 
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TABLE 10: Effect of EEDE on serum lipid profile  
Groups Serum 
cholesterol 
(mg/dL) 
Triglycerides 
(mg/dL) 
HDL-C 
(mg/dL) 
LDL-C 
(mg/dL) 
VLDL-C 
(mg/dL) 
Normal 
control 
66.23± 3.98 
 
58.21± 2.40 37.97± 4.8 17.91± 2.60 12.43± 2.16 
Positive 
control 
170.58± 
10.57 
 
145.8± 8.18 21.67±2.80 118.3± 7.16 28.67± 3.733 
Standard 110.5± 
3.73*** 
 
95.83± 
3.31*** 
 
33.83± 
3.18*** 
48.50± 
3.55*** 
18.73± 
2.51*** 
EEDE 
250mg/kg 
136.9± 
4.16*** 
 
 
120.00± 
4.74*** 
 
27.47± 
2.60ns 
87.00± 
3.23*** 
21.70± 
2.739** 
EEDE-
500mg/kg 
122.5± 
4.88*** 
 
 
107.8± 
3.76*** 
 
31.5± 2.73* 68.33± 
2.58*** 
21.83± 
3.18*** 
Values are expressed as mean ± SD (n=6).Values were significant when compared 
with cholesterol group. * P<0.05, ** P<0.01, ***P<0.001 (one way ANOVA 
followed by Dunnet test)          
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Graph II Effect of EEDE on lipid profiles TC, TG, LDL, VLDL, 
HDL levels in cholesterol induced rats 
 
Values are expressed in Mean for six animals. 
 
TABLE-11: Effect of EEDE on serum kidney biomarkers in normal and cholesterol 
rats. 
GROUPS UREA 
(mg/dL) 
CREATININE(mg/dL) URIC ACID 
(mg/dL) 
Normal control 
 
Positive control 
 
Standard  
 
EEDE-
250mg/kg 
 
EEDE-
500mg/kg 
17.2±2.30 
 
18.1±3.2 
 
11.2±1.70*** 
 
13.5±0.80* 
 
 
12.8±0.60* 
0.43±0.101 
 
0.85±0.12 
 
0.44±0.108*** 
 
0.63±0.09* 
 
 
0.61±0.07* 
2.1±0.50 
 
4.80±1.4 
 
1.29±0.10*** 
 
1.69±0.51*** 
 
 
1.38±0.23*** 
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 Values are expressed as mean ± SD (n=6).Values were significant when 
compared with positive control group. * P<0.05, **P<0.01, ***P<0.001 (one way 
ANOVA followed by Dunnet test). 
Graph III: Effect of EEDE on serum kidney biomarkers urea, 
creatinine, uric acid levels in cholesterol induced rats. 
Values are expressed in Mean± SD for six animals. 
 
TABLE-12: Effect of EEDE on antioxidant enzymes in control and 
experimental rats. 
GROUPS SOD CATALASE GSH 
Normal control 
 
Positive control 
 
Standard  
 
EEDE 250mg/kg 
 
EEDE 500mg/kg 
6.89± 0.60 
 
5.00± 0.61 
 
5.64± 0.72* 
 
6.72± 0.87*** 
 
6.61± 0.63*** 
12.38± 0.81 
 
7.31± 0.69 
 
8.36± 0.64ns 
 
8.41± 0.75** 
 
8.73± 0.60*** 
35.76±1.16 
 
14.39±0.56 
 
21.12±0.98*** 
 
23.54±1.16*** 
 
29.27±1.87*** 
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 Values are expressed as mean ± SD (n=6).Values were significant when 
compared with cholesterol group. * P<0.05, **P<0.01, ***P<0.001 (one way 
ANOVA followed by Dunnet test). 
Graph IV: Effect of EEDE on antioxidants of SOD, CAT and GSH 
levels in cholesterol induced rats 
 
 
Values are expressed in Mean± SD for six animals. 
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5.5. Histopathological studies 
 
         
     Normal control of Heart 10X          Positive control Heart 10X 
             
  Standard group of Heart 10X               EEDE 250mg/kg of heart 10X      
 
EEDE 500mg/kg of heart 10X 
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7. DISCUSSION 
Hyperlipidemia means presence of a high amount of cholesterol in the body 
has been demonstrated to elevate total cholesterol and may increase the risk of 
atherosclerosis and lead to cardiovascular disease. Herbs play a key role in the 
management of various CVD. Numerous medicinal plants and their formulations are 
used for hyperlipidemia in ethnomedical practices and in traditional system of 
medicine in India. However, we do not satisfactory remedy for hyperlipidemia; most 
of the herbal drugs speed up the reduction of cholesterol by healthy dietary intake. 
So, the search for anti-hyperlipidemic activity of high cholesterol induced rats. 
The extraction by soxhlet method for 100gms of powder yielded 12.8%. The 
preliminary phytochemical screening revealed the presence of Carbohydrates, 
Alkaloids, Glycosides, Flavonoids, Tannins, Phenolic compounds, Amino acid, 
Saponins, Steroids, Gums and Proteins [Tijare R D et al., 2012]. The extract was 
found safe up to a dose of 5000mg/kg body weight. The dried extract was suspended 
in 1% CMC at dose levels 250mg/kg and 500mg/kg body weight for oral 
administration. 
Cholesterol powder was purchased and used with normal diet shows changes 
in serum cholesterol levels differ significantly between rats and humans [Suckling 
KE et al., 1993]. To clarify these confusions, a 12 week’s feeding study with rats 
was conducted to evaluate the influence of high fat diet on serum lipid profiles, 
kidney parameters and antioxidant studies. 
The use of rats as experimental animals for hyperlipidemic activity is mainly 
due to the synthesis and structural similarities in human and rats. 
The present study carried out inducing 5% cholesterol for the experimental 
induction in rats. Cholesterol will deposits in the endothelial cells and transport with 
lipoproteins in blood stream which leads to increase in the TC, TG, LDL, VLDL 
levels and decreases the HDL levels in the body. It is synthesised in the liver and 
converted into bile acids and excreted through faeces and due to hypercholestremia 
urine failure will occur due to oxidative stress. 
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Statins are a class of drugs used to lower cholesterol levels by inhibiting the 
enzyme HMG-CoA reductase, which plays a central role in the production of 
cholesterol in the liver. Rosvastatin is a competitive inhibitor of HMG-CoA 
reductase and catalyzes the reduction of 3-hydroxy-3-methylglutaryl-
coenzymeA (HMG-CoA) to mevalonate, which is the rate-limiting step in 
hepatic cholesterol biosynthesis. Inhibition of the enzyme decreases hepatic 
cholesterol, increasing expression of low-density lipoprotein receptors (LDL 
receptors) on hepatocytes and decrease the amount of LDL-cholesterol in the blood. 
Like other statins, rosvastatin also reduces blood levels of triglycerides and slightly 
increases levels of HDL-cholesterol [Villa J et al., 2010 and McCormack T et al., 
2010]. 
The assessment of cholesterol function can be made by estimating the body 
weight and activities of various lipid profiles such as TC, TG, HDL, LDL and 
VLDL; kidney parameters such as urea, creatinine and uric acid. 
Body weight can be increased due to the high cholesterol diet induced in 
hyperlipidemia rats. As the dietary fat, FFAs can be synthesised into many tissues 
by transport of increased lipoproteins in the blood stream absorbed from the 
intestine and metabolised in liver [Van Heek et al., 2000]. The EEDE treatment and 
Rosvastatin drug significantly lower the body weight by the reduction in the LDL, 
VLDL levels and increase HDL levels. 
TC and TG are present in dietary fat, FFAs combine with glycerol to form 
TG and cholesterol is esterified by ACAT to form cholesterol esters, storing 
cholesterol in cells [Lombardo et al., 1980]. TC and TG are generated by the liver 
and circulate as chylomicrons interact at capillaries of adipose tissues and muscle 
cells. LPL hydrolyzes the TG, and FFAs are released. The elevated TC and TG 
levels in hyperlipidemia induced high cholesterol diet are due to the increase of 
cholesterol in capillary cells. The EEDE treatment and Rosvastatin drug 
significantly lowered the abnormal levels of TC and TG might be due to lowering of 
FFA (Free fatty acids) synthesis in the plasma. 
LDL and VLDL are package of TG and TC esters in liver and released into 
blood circulation. VLDL is then hydrolyzed by LPL in tissues to release fatty acids 
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taken up by muscle cells for energy and glycerol becomes a VLDL remnant taken up 
by the liver by LDLR. They hydrolyzed in the liver by HL to form LDL. LDLR 
activity and uptake regulates plasma LDL concentration through decreasing the 
synthesis of HMG-CoA reductase controls the rate of de novo cholesterol synthesis 
by the cell [Sabrin R. M. Ibrahim et al., 2013]. LDL and VLDL levels are increased 
due to the suppression of synthesis of new LDLR in the cells, activates the enzyme 
ACAT, free cholesterol into cholesterol ester by cholesterol diet. The EEAG and 
Rosuvastatin treatment significantly decrease the LDL and VLDL levels in the liver.  
HDL is a key lipoprotein involved in reverse cholesterol transport and 
transfer of cholesterol esters between lipoproteins and secreted by the liver and 
intestine proceeds through a series of conversions known as the HDL cycle. It 
attracts cholesterol from cell membranes and free cholesterol to the core of the HDL 
particle, inhibiting the oxidation of LDL and by neutralizing the atherogenic effects 
of oxidizes LDL [Parthasarathy S et al., 1990]. The EEDE and Rosvastatin treatment 
significantly increase the HDL levels due to the synthesis of the liver by converting 
bile into bile acids and excreated through faeces by decrease TC and TG levels. 
Flavonoids can increase HDL-C and also decreases oxidation of LDL- cholesterol 
[Akila M et al., 2008]. 
Urea, uric acid and creatinine levels were increase due to the high cholesterol 
diet [Sudhahar et al., 2008]. There is a association between hypercholesterolemia 
and kidney damage in which the oxidative stress and inflammatory responses are 
involved in renal injury was up regulated by hypercholesterolemic condition. 
Oxidative stress might play a patophysiological role due to increase of MDA levels 
present in higher lipid group due to impaired pro-oxidant and antioxidant 
mechanism [Kumari S.S et al., 1987]. Altered physical properties of cellular 
membrane may facilitate the escape of free radicals from mitochondrial electron 
transport chain leads to lipid peroxidation and cell oxidative injury [Engelmann B et 
al., 1992 and Ludwig P.W et al., 1982].Further hypercholesterolemia associated with 
oxidative modification of LDL, Protein glycation, glucose auto oxidation leads to 
elevated oxidative stress. The treatment with EEDE and rosavastatin significantly 
decrease the levels of urea, uric acid and creatinine when compare to hyperlipidemia 
group. 
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Antioxidant defence enzymes SOD, CAT and GSH, protect the aerobic cells 
against oxygen stress and lipid peroxidation. SOD and GSH are the first line of 
cellular defence against oxidative injury by excess free radical production which is 
involved in the disposal of superoxide radical to hydrogen peroxide and catalase 
converts H2O2 to H2O. Low SOD and GSH activity attribute inactivation of enzyme 
by ROS bringing damage to proteins. GSH is a stable enzyme inactivated by severe 
oxidative stress [Condell R.A et al., 1983] due to hyperlipidemia. The declined 
levels of lipid peroxidation in EEDE and rosavastatin treated rats contribute to the 
potential inhibitors of lipid peroxidation due to the presence of polyphenols like 
flavonoids, tannins  and phenolics as they are reported to exhibit antioxidant 
properties. 
The histological studies reveals that the heart sections treated/induced with 
cholesterol showed a marked fat cells in the heart with can be increase the lipid 
peroxidation due to oxidative stress causes increase the TC, TG, LDL, VLDL levels 
in positive group when compare to normal group result decrease levels of 
lipoproteins and show the normal architecture of heart cells. 
Animals treated with rosovastatin showed a significant restoration of 
lipoproteins in the heart by maintaining ROS production whereas group IV and V 
animals treated with EEDE preserved the architecture of heart cells by reducing the 
free fatty acids exhibiting antihyperlipidemic activity. 
Naturally occurring flavonoids and saponins can reduce the excess 
production of LDL and VLDL levels and increase the HDL levels in the tissues. 
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8. SUMMARY & CONCLUSION 
 
     The aim of the study is to evaluate the antihyperlipidemic activity of the 
ethanolic extract of aerial part of Delonix elata in cholesterol diet induced 
hyperlipidemic rats.  
 
Wistar albino rats were randomly divided into five groups of six each. 
Group-I served as normal control. Groups II to V were given 5% cholesterol diet for 
3 months to induce hyperlipidemia, and for last 28 days were administered either: 
0.5ml water/saline for Group- I; cholesterol diet (5%) for Group-II; Standard drug 
Rosuvastatin (20mg/kg body weight) for Group-III; EEDE at 250 mg/kg bodyweight 
for Group-IV and 500mg/kg body weight for Group-V. The effects of EEDE on 
Body Weight, serum lipid profile, kidney parameters and anti oxidant enzymes 
(superoxide dismutase, GSH and catalase) were assessed and compared. 
 
Cholesterol diet induced hyperlipidemic rats showed an significant 
(P<0.001) increase in the plasma concentration of Total Cholesterol (TC), 
Triglycerides (TG), Low-Density Lipoprotein cholesterol (LDL-c), Very Low-
Density Lipoprotein cholesterol (VLDL-c), Body weight and kidney parameters; it 
decrease in High Density Lipoproteins Cholesterol (HDL-c) and antioxidant 
enzymes when compared to normal control rats. Co-administration of EEDE and 
standard drug Rosuvastatin with cholesterol diet caused a significant decrease 
(p<0.001) in the concentration of serum TC, VLDL, TG, body weight and kidney 
parameters; increase in the HDL-C and antioxidant enzymes when compared with 
cholesterol fed control rats. The result suggests lipid lowering effects of Delonix 
elata which serves as a new potential natural product for preventing hyperlipidemia. 
 
In this conclusion, the findings of the study suggest that Delonix elata is a 
potent for antihypercholesterolemic, antihypertriglycerolemic drug lowering LDL, 
VLDL and increasing HDL levels in all the High cholesterol diet treated groups. The 
mechanism has point towards inhibiting cholesterol and triglyceride synthesis. 
Aerial parts of Delonix elata proved to be effective at higher doses (500mg/kg) and 
Rosuvastatin standard drug shows better results in decrease TC, TG, LDL and 
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VLDL levels and increase the HDL levels compare to hyperlipidemia rats. The urea, 
creatinine and uric acid levels are decreased with EEDE compare to the 
hyperlipidemia rats. In hyperlipidemic rats, the increases of antioxidant enzymes- 
SOD, CAT and GSH due to the free radical mechanism which could be reduces with 
help of EEDE groups. Therefore, it can be recommended for further investigation to 
reveal the exact mechanism for hyperlipidemia activity. 
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